365 Epigenetic Profiling Reveals a Unique Histone Code in Chordoma |
|
Activity of Sorafenib against desmoid tumor/deep fibromatosis |
|
Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program |
|
Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy. |
|
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab |
|
Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors. |
|
A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors |
|
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement |
|
G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. |
|
Genomic aberrations frequently alter chromatin regulatory genes in chordoma |
|
Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials |
|
Inclusion of patients with brain metastases in phase I trials: an unmet need. |
|
Locally Aggressive Connective Tissue Tumors. |
|
Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor |
|
Moving forward one Notch at a time |
|
Multidisciplinary management of recurrent chordomas |
|
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. |
|
Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials |
|
Notch inhibition in desmoids: "Sure it works in practice, but does it work in theory?" |
|
OncoKB: A Precision Oncology Knowledge Base |
|
Outcomes of Systemic Therapy for Patients with Metastatic Angiosarcoma |
|
The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA |
|
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma |
|
Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. |
|
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel |
|
Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations |
|
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma |
|
Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma. |
|
Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials |
|
Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment |
|
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial. |
|
Quantitative method for the determination of iso-fludelone (KOS-1803) in human plasma by LC-MS/MS. |
|
Reply to M. Voskoboynik et al |
|
Sorafenib for Advanced and Refractory Desmoid Tumors |
|
Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network |
|
Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities |
|
Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation. |
|
Tumor mutational load predicts survival after immunotherapy across multiple cancer types |
|
진행성 고형종양 환자에서 엔도시알린에 대한 단일클론항체인 MORAb-004에 대한 인간 최초 임상 1상 연구 |
|